CHA
XENE icon

Carmichael Hill & Associates’s Xenon Pharmaceuticals XENE Stock Holding History

Carmichael Hill & Associates’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-80
Closed -$1K – 839
2021
Q3 		$1K Hold
80
– – ﹤0.01% 785
2021
Q2 		$1K Hold
80
– – ﹤0.01% 764
2021
Q1 		$1K Buy
80
+15
+23% +$254 ﹤0.01% 750
2020
Q4 		$1K Buy
65
+40
+160% +$468 ﹤0.01% 727
2020
Q3 		$0 Buy
+25
New +$294 ﹤0.01% 742

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Carmichael Hill & Associates's XENE Position: Q4 2021 in Review

Carmichael Hill & Associates sold out of Xenon Pharmaceuticals (XENE) in Q4 2021, closing a stake of 80 shares — an estimated $1K sold.

Carmichael Hill & Associates first reported a position in XENE in Q3 2020 and held it in 5 quarters. The position peaked at $1K in Q3 2021. 130 funds tracked by Wall St. Rank hold XENE as of Q4 2021.

  • Carmichael Hill & Associates reported no remaining Xenon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 80 Xenon Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Carmichael Hill & Associates first reported a position in Xenon Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Carmichael Hill & Associates's Xenon Pharmaceuticals position peaked at $1K in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2021.

Based on Carmichael Hill & Associates's 13F filing for Q4 2021, filed 31 Jan 2022.